$19.35
-0.08 (-0.41%)
Open$19.24
Previous Close$19.43
Day High$19.46
Day Low$19.05
52W High$34.19
52W Low$14.72
Volume—
Avg Volume682.5K
Market Cap1.09B
P/E Ratio—
EPS$-2.07
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 7.14M | 9.1K | 117.17M |
| Net Income | -69,986,017 | -50,362 | -10,038,830 |
| Profit Margin | -980.9% | -582.6% | -8.6% |
| EBITDA | -79,452,456 | -48,936 | -16,056,956 |
| Free Cash Flow | — | — | -11,744,338 |
| Rev Growth | +147.5% | +60.5% | +1.7% |
| Debt/Equity | — | 0.51 | 0.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |